Facebook
  • Brinzolamide CAS 138890-62-7
  • 99% Brinzolamide CAS 138890-62-7: The Gold Standard in Glaucoma Management
  • 99% Brinzolamide CAS 138890-62-7: The Gold Standard in Glaucoma Management
  • 99% Brinzolamide CAS 138890-62-7: The Gold Standard in Glaucoma Management
  • 99% Brinzolamide CAS 138890-62-7: The Gold Standard in Glaucoma Management
  • 99% Brinzolamide CAS 138890-62-7: The Gold Standard in Glaucoma Management
  • 99% Brinzolamide CAS 138890-62-7: The Gold Standard in Glaucoma Management
  • Brinzolamide CAS 138890-62-7
  • 99% Brinzolamide CAS 138890-62-7: The Gold Standard in Glaucoma Management
  • 99% Brinzolamide CAS 138890-62-7: The Gold Standard in Glaucoma Management
  • 99% Brinzolamide CAS 138890-62-7: The Gold Standard in Glaucoma Management
  • 99% Brinzolamide CAS 138890-62-7: The Gold Standard in Glaucoma Management
  • 99% Brinzolamide CAS 138890-62-7: The Gold Standard in Glaucoma Management
  • 99% Brinzolamide CAS 138890-62-7: The Gold Standard in Glaucoma Management

99% Brinzolamide CAS 138890-62-7: The Gold Standard in Glaucoma Management

No.FH-M1659
Discover Brinzolamide CAS 138890-62-7, the premier choice for managing glaucoma and ocular hypertension. With its selective inhibition of carbonic anhydrase, Brinzolamide effectively reduces intraocular pressure, promoting vision preservation and patient compliance. Ideal for pharmaceutical formulations, this high-quality ingredient offers long-term stability and a favorable safety profile. Contact us today to learn more.
$60.50
MOQ:
1kg
Free sample:
Available
  • Brinzolamide CAS 138890-62-7
  • 99% Brinzolamide CAS 138890-62-7: The Gold Standard in Glaucoma Management
  • 99% Brinzolamide CAS 138890-62-7: The Gold Standard in Glaucoma Management
  • 99% Brinzolamide CAS 138890-62-7: The Gold Standard in Glaucoma Management
  • 99% Brinzolamide CAS 138890-62-7: The Gold Standard in Glaucoma Management
  • 99% Brinzolamide CAS 138890-62-7: The Gold Standard in Glaucoma Management
  • 99% Brinzolamide CAS 138890-62-7: The Gold Standard in Glaucoma Management

Description

Brinzolamide CAS 138890-62-7

Brinzolamide, with its Chemical Abstracts Service (CAS) registry number 138890-62-7, is a highly specialized pharmaceutical compound belonging to the class of carbonic anhydrase inhibitors. This potent molecule has garnered significant attention in the ophthalmic industry due to its efficacy in managing intraocular pressure (IOP), a critical factor in the management of glaucoma and other ocular hypertensive conditions. comprehensive guide, we delve into the intricacies of Brinzolamide, its mechanisms of action, applications, safety profile, and why it stands out as a premier choice for healthcare professionals worldwide.

Mechanism of Action

Brinzolamide functions by selectively inhibiting carbonic anhydrase, an enzyme responsible for catalyzing the conversion of carbon dioxide and water into bicarbonate and protons within the eye. By inhibiting this enzyme, Brinzolamide reduces the production of aqueous humor, the clear fluid that fills the anterior and posterior chambers of the eye. This, in turn, a decrease in intraocular pressure, helping to preserve vision and prevent further damage to the optic nerve caused by glaucoma.

Key Applications

  • Glaucoma Management: As a first-line or adjunctive therapy, Brinzolamide effectively controls IOP in patients with open-angle glaucoma hypertension.
  • Post-Surgical Care: Following certain ocular surgeries, such as cataract extraction or trabeculectomy, Brinzolamide can be prescribed to maintain optimal IOP levels and aid in a successful recovery.
  • Complementary Therapy: It can be used in conjunction with other anti-glaucoma medications to enhance overall therapeutic outcomes and patient compliance.

Safety & Tolerability

Brinzolamide is generally well-tolerated, with a favorable safety profile. However, like all medications, it may cause side effects in some individuals, including blurred vision, eye irritation, or taste alterations due to its potential to reach the nasolacrimal duct. It's crucial for healthcare providers to thoroughly assess patient history and monitor for adverse reactions, particularly in those with known hypersensitivity to sulfonamides or related compounds.

Unique Selling Points

  • Selective Brinzolamide targets a specific isoform of carbonic anhydrase, minimizing off-target effects and enhancing efficacy.
  • Long-Term Stability: Its ability to maintain stable IOP reduction over extended periods makes it an attractive option for chronic glaucoma management.
  • Patient Compliance: The convenient dosing regimen and minimal systemic absorption contribute to high patient acceptance and adherence.

Conclusion

Brinzolamide CAS 138890-62-7 is a cornerstone in the management of glaucoma and ocular hypertension, offering a precise and effective means of controlling intraocular pressure.-established mechanism of action, favorable safety profile, and ease of use make it a valuable addition to any ophthalmologist's armamentarium. For pharmaceutical companies seeking reliable and high-quality ingredients for their ophthalmic formulations, Brinzolamide represents an excellent choice.

Download

Message Us